NKTR
Closed
Nektar Therapeutics
24.59
-1.25 (-4.84%)
Last Update: 01 Jul 2025 23:21:00
Yesterday: 25.84
Day's Range: 24.1899 - 25.74
Send
sign up or login to leave a comment!
When Written:
0.7912
Nektar Therapeutics is a biopharmaceutical company that develops innovative medicines to address unmet medical needs. The company was founded in 1990 and is headquartered in San Francisco, California. Nektar's mission is to improve patient outcomes by developing and commercializing medicines that treat serious diseases, including cancer, autoimmune disorders, and chronic pain.
Nektar's drug development pipeline includes several promising candidates, including:
1. Bempegaldesleukin (BEMPEG): A first-in-class, investigational, IL-2 pathway agonist designed to stimulate the patient's immune system to fight cancer.
2. NKTR-358: A novel, investigational therapy designed to stimulate regulatory T cells (Tregs) in order to treat autoimmune diseases.
3. NKTR-181: A first-in-class, oral opioid analgesic designed to provide pain relief without the euphoria and addiction potential of traditional opioids.
Nektar has partnerships with several leading pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Eli Lilly. The company has a strong track record of successful partnerships, which has helped to advance its drug development programs and expand its reach in the global healthcare market.
Nektar has a highly experienced management team and a strong financial position, with a market capitalization of over $4 billion as of 2021. The company is committed to delivering innovative medicines that improve patient outcomes and is well-positioned for continued growth and success in the biopharmaceutical industry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Nektar's drug development pipeline includes several promising candidates, including:
1. Bempegaldesleukin (BEMPEG): A first-in-class, investigational, IL-2 pathway agonist designed to stimulate the patient's immune system to fight cancer.
2. NKTR-358: A novel, investigational therapy designed to stimulate regulatory T cells (Tregs) in order to treat autoimmune diseases.
3. NKTR-181: A first-in-class, oral opioid analgesic designed to provide pain relief without the euphoria and addiction potential of traditional opioids.
Nektar has partnerships with several leading pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Eli Lilly. The company has a strong track record of successful partnerships, which has helped to advance its drug development programs and expand its reach in the global healthcare market.
Nektar has a highly experienced management team and a strong financial position, with a market capitalization of over $4 billion as of 2021. The company is committed to delivering innovative medicines that improve patient outcomes and is well-positioned for continued growth and success in the biopharmaceutical industry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!